Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability

Gilead Sciences’ HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time. | Gilead’s HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time, as highlighted by CEO Daniel O’Day. But one group of analysts is raising doubts about the long-term growth of Yeztugo, the company’s much-touted long-acting PrEP option.